Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Subscribe To Our Newsletter & Stay Updated
